Global EPO Biomarkers Market Research and Forecast 2018-2023 - The Upcoming Patent Expiration of EPO Biomarkers is Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Global EPO Biomarkers Market Research and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering.
Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits has increased the prevalence of cancers and chronic kidney diseases in the emerged economies.
Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers.
The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market.
Improper price capping regulations across the globe is another factor that is significantly responsible in hampering the growth of the global EPO biomarkers market. However, the favorable healthcare regulations in emerged economies such as the U.S. and rising prevalence of chronic diseases such as cancer is expected to fuel the market growth in the near future.
Among biomarker type, the erythropoietin alfa segment holds a major share in the global EPO biomarkers market. This is owing to increasing adoption in the treatment of chronic renal disorders and cancer.
North America holds a dominant position in the global EPO biomarkers market, followed by Europe. This is mainly owing to the developed healthcare infrastructure in the region. Moreover, the systematic initiatives taken by the government in the research and development activities is one of the major factors contributing in the growth of the EPO biomarkers market in the region.
Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are low cost of treatment therapy and increasing incidence rate of hematological diseases in the region, especially in India, China, Pakistan, and Bangladesh.
Some of the key players operating in the global EPO biomarkers market are Siemens AG, Thermo Fisher Scientific, Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., Merck KGaA, LG Lifesciences Pvt Ltd, Amgen Inc., F. Hoffmann-LA Roche Ltd, and Agilent Technologies, Inc., among others.
In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance, in January 9, 2017, the Amgen Inc. has signed an agreement with DaVita Inc., a US-based healthcare solution provider. According to the agreement, the Amgen Inc. will supply DaVita’s EPOGEN (epoetin alfa) and Aranesp (darbepoetin alfa) in the U.S. and Puerto Rico.
Key Topics Covered
Chapter 1. Report Summary
1.1. Research Methods And Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
Chapter 2. Market Overview And Insights
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
126.96.36.199. United States
188.8.131.52. European Union
Chapter 3. Market Determinant
3.1.1. Increasing Incidence Of Cancers And Renal Disorders
3.1.2. Sedentary Lifestyle And Faulty Dietary Habits
3.1.3. Increasing Prevalence Of Chronic Kidney Diseases Such As Diabetes
3.1.4. Upcoming Patent Expiration Of Epo Biomarkers
3.2.1. Less Of Quality Control Testing Laboratories In Emerging Economies
3.3.1. Favorable Healthcare Regulations In Emerged Economies
Chapter 4. Market Segmentation
4.1. Global Epo Biomarker Market, By Biomarker Type
4.1.1. Erythropoietin Alfa
4.1.2. Erythropoietin Beta
4.1.3. Erythropoietin Zeta
4.1.4. Erythropoietin Theta
4.1.5. Recombinant Human Erythropoietin
4.1.6. Darbepoietin Alfa
4.2. Global Epo Biomarker Market, By Applications
4.2.1. End-Stage Renal Disorder
4.2.3. Rheumatoid Arthritis
4.2.5. Myelodysplastic Syndrome
4.2.8. Others (Anaemia Of Chronic Inflammatory Syndromes)
4.3. Global Epo Biomarker Market, By End Users
4.3.1. Diagnostic Centers
4.3.2. Ambulatory Care And Surgical Centers
Chapter 5. Competitive Landscape
Chapter 6. Regional Analysis
6.1. North American
6.3. Asia Pacific
6.4. Rest Of The World
Chapter 7. Company Profiles
7.1. 3Sbio Group
7.2. Agilent Technologies, Inc.
7.3. Amgen Inc.
7.4. Bioagilytix Labs
7.6. Bio-Rad Laboratories, Inc.
7.7. Eve Technologies
7.8. F. Hoffmann-La Roche Ltd
7.9. Galenica Ag
7.11. Glaxosmithkline Plc.
7.12. Intas Pharmaceuticals Ltd.
7.13. Johnson & Johnson Services, Inc.
7.14. Kyowa Hakko Kirin Co., Ltd.
7.15. Lg Lifesciences Pvt Ltd
7.16. Merck Kgaa
7.17. Myriad Rbm
7.18. Novartis Ag
7.19. Pacific Biomarkers
7.20. Pfizer Inc.
7.21. Sandoz International Gmbh
7.22. Shandong Kexing
7.23. Siemens Ag
7.24. Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/research/s6kgf8/global_epo?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005456/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/30/2018 01:42 PM/DISC: 11/30/2018 01:42 PM